India, May 15 -- Aura Biosciences, Inc. (AURA), a clinical-stage biotech firm focused on precision therapies for solid tumors, has announced a public offering of its common stock and related warrants.
The offering includes shares of common stock, pre-funded warrants for certain investors, and accompanying common stock purchase warrants. All securities will be issued by Aura. Completion and terms of the offering remain subject to market conditions.
The offering is being conducted under a shelf registration statement (Form S-3, file no. 333-278253) that became effective on April 5, 2024. The securities will be sold only through a prospectus and accompanying prospectus supplement. These documents will be filed with the SEC and made available...